Overview
Cumberland Q2 2025 revenue rises 10% yr/yr to $10.8 mln
Year-to-date revenue up 23% over first half of 2024
Co announces Vibativ 4-Vial Starter Pak availability through Vizient
Outlook
Company expresses optimism for continued success in clinical programs
Cumberland optimistic about building on first-half success
Result Drivers
PRODUCT PORTFOLIO - FDA-approved brands contributed to a 10% revenue increase in Q2 2025
VIBATIV AVAILABILITY - New supply arrangement with Vizient enhances Vibativ treatment flexibility
CLINICAL PROGRESS - Phase II FIGHT DMD trial shows promising results for ifetroban in improving cardiac function
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $10.80 mln | ||
Q2 Operating Expenses | $11.60 mln |
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Press Release: ID:nPn3qxwh8a
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.